RxDoctor Payments Data

John Kalin, MD

Cardiovascular Disease · Hyannis, MANPI 1295783447

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $387,885 of the $447,603 with a category attached, or 86.7%. 39 manufacturers reported payments, led by Johnson & Johnson at 29.5% of the total. Reporting peaked in 2019 at $131,310 and has fallen 83.7% since, to $21,416 in 2025. Among cardiovascular disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$447,603in general payments, 2019–2025

Across 1,148 payments — averaging $389.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$132K
  • Boehringer Ingelheim$64K
  • E.r. Squibb & Sons, L.L.C.$52K
  • Amgen$42K
  • Lexicon Pharmaceuticals, Inc.$41K
  • AstraZeneca$26K
  • plus $90K from 33 others

What the payments were for

  • Consulting fees$7,1972%
  • Speaking & faculty fees$387,88587%
  • Travel & lodging$26,3686%
  • Food & beverage$26,0306%
  • Education$1240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$447,603 in reported general payments places this provider in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$791,742
Medicare patients
1,152
Services billed
7,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban408$593,782
EntrestoSacubitril/Valsartan278$400,212
XareltoRivaroxaban217$295,596
JardianceEmpagliflozin102$115,952
FarxigaDapagliflozin Propanediol99$104,380
Repatha SureclickEvolocumab34$35,822
InpefaSotagliflozin17$16,916
Praluent PenAlirocumab23$16,224
VerquvoVericiguat11$14,992
Repatha PushtronexEvolocumab12$11,499
Metoprolol Succinate520$9,326
Atorvastatin Calcium530$8,575
Dabigatran EtexilateDabigatran Etexilate Mesylate20$7,949
VascepaIcosapent Ethyl12$7,310
Rosuvastatin Calcium176$6,576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12,366$593,782408 claims
NovartisEntresto$18,045$400,212278 claims
Johnson & JohnsonXarelto$131,911$295,596217 claims
Boehringer IngelheimJardiance$63,906$115,952102 claims
AstraZenecaFarxiga$26,465$104,38099 claims
Lexicon Pharmaceuticals, Inc.Inpefa$41,429$16,91617 claims
MerckVerquvo$587$14,99211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Hyannis

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →